Zota Health Care Ltd. · NSE:ZOTA
Zota Health Care — Q3 FY2022 Earnings Presentation
29 slides from Zota Health Care's earnings presentation, Feb 17, 2022
Slide 1: Cover letter to NSE: Investor Presentation
} zoto' healthcare ltd. Fe*uary 17 ,2022 To, The Manager Listing Department, The National Stock Exchange of lndia [imited Exchange Plaza, Bandra Kurla Complex, Ba ndra (E), Mumbai - 400051 Dear Sir/Madam, Trading Symbol: ZOTA Sub: lnvestor Presentation Ref: Regulation 30 of SEBI (Listing Obligations
Slide 2: Q3FY22 Performance Highlights
Q3FY22 PERFORMANCE HIGHLIGHTS FEBRUARY 2022
Slide 3: Safe Harbour
Safe Harbour This presentation has been prepared by the Zota Health Care Limited (the “Company”) only for information purpose to the stakeholders and does not contain any offer or invitation to subscribe the securities of the Company. No offering of securities shall be made except by means of offer
Slide 4: Table Of Contents
Table Of Contents 01 RESULT HIGHLIGHTS 02 OPERATIONAL METRICS 03 DAVAINDIA BUSINESS OUTLOOK 04 & STRATEGY 05 FINANCIAL SUMMARY zotahealthcare.com
Slide 5: Q3FY22 Result Highlights
Q3FY22- Result Highlights zotahealthcare.com
Slide 6: Standalone Quarterly Financial Highlights
Stand Quarterly Financial Highlights Q-o-Q Revenues (₹ Lakhs) Gross Profit (%) Operating Profit (₹ Lakhs) PAT (₹ Lakhs) Q3-FY22 3,093.88 Q3-FY22 39.93% Q3-FY22 516.50 Q3-FY22 354.23 Q2-FY22 3,539.70 Q2-FY22 33.82% Q2-FY22 493.62 Q2-FY22 331.63 Y-o-Y Revenues (₹ Lakhs) Gross Profit (%) Operating Prof
Slide 7: Standalone 9-Month Financial Highlights
Stand 9-Month Financial Highlights Y-o-Y Revenues (₹ Lakhs) Gross Profit (%) 9M-FY22 9,978.07 9M-FY22 35.78% 9M-FY21 7,619.86 9M-FY21 32.07% Operating Profit (₹ Lakhs) PAT (₹ Lakhs) 9M-FY22 1,498.76 9M-FY22 1,023.27 9M-FY21 81.81 9M-FY21 51.82 06 zotahealthcare.com
Slide 8: Revenue Break up – Quarterly
Revenue Break up – Quarterly Domestic Sales Dava India Sales Export Sales (SEZ) 1,699.9 910.4 848.1 1,020.3 991.7 1,452.6 1,334.5 693.5 739.5 Q3-FY21 Q2-FY22 Q3-FY22 Q3-FY21 Q2-FY22 Q3-FY22 Q3-FY21 Q2-FY22 Q3-FY22 07 zotahealthcare.com
Slide 9: FY Result Highlights
FY- Result Highlights zotahealthcare.com
Slide 10: Standalone Profit & Loss Statement - Quarterly
Stand Profit & Loss Statement - Quarterly Particulars (Rs Lakhs) Q3FY22 Q2FY22 YoY % QoQ % Q3FY21 Export Sales (SEZ) 739.54 991.70 -28% -25% 1,020.25 Dava India Sales 910.38 848.10 31% 7% 693.50 Domestic Sales 1452.56 1699.90 9% -15% 1,334.52 Revenues from Operations 3,093.88 3,539.70 1% -13% 3,048.
Slide 11: Management Commentary
Management Commentary 01 The Company reported a 02 Exports performance suffered 03 The sales contribution from decrease in Revenues in a 25% decline QoQ and 28% new-age business stood at Q3FY22 on a QoQ basis, YoY, due to prolonged 53% in Q3FY22 as compared primarily due to lower export container sh
Slide 12: Management Commentary: Domestic Operations and Exports
Management Commentary DOMESTIC OPERATIONS Domestic Revenues EBITDA at ₹ 317.68 PAT stood at ₹ registered a decline of 7% Lakhs for Q3FY22, 171.08 Lakhs for QoQ and a growth of 17% backed by surge in Q3FY22. YoY at ₹ 2362.9 Lakhs Davaindia revenue. supported by healthy performance in both verticals.
Slide 13: Davaindia Generic Pharmacy
Davaindia Generic Pharmacy zotahealthcare.com
Slide 14: Davaindia Key Figures
Davaindia Key Figures Gross Mercantile Value (GMV) Total GMV of Davaindia Stores stood at 1501 Lakhs during Q3FY22 up 7% QoQ and 31% YoY. No. of SKU’s New Stores rolled-out 1,614 55 49 1,585 34 1,503 Q1-FY22 Q2-FY22 Q3-FY22 Q1-FY22 Q2-FY22 Q3-FY22 13 zotahealthcare.com
Slide 15: Davaindia Key Figures: Customers and Wallet Spend
zotahealthcare.com During Q3FY22, up by 5% QoQ and 76% YoY 5,68,183 Q3-FY22 5,40,924 Q2-FY22 No. of Customers Served 4,73,181 Q1-FY22 4,40,458 Q4-FY21 3,23,395 Q3-FY21 3,52,623 Q2-FY21 3,38,415 Q1-FY21 Davaindia Key Figures 2,75,520 Q4-FY20 2,67,030 Q3-FY20 237 Q3-FY22 229 Q2-FY22 220 Q1-FY22 Averag
Slide 16: Davaindia - Generic Pharmacy
Davaindia- Generic Pharmacy During the quarter Davaindia has Davaindia has led the revolution of Davaindia retail pharmacy stores’ catered to the highest-ever number of patients opting for generic medicines focus continues to be chronic ailments customer i.e. 5.68 lakhs against 5.41 against branded
Slide 17: Davaindia - Generic Pharmacy
Davaindia- Generic Pharmacy 16 zotahealthcare.com
Slide 18: Davaindia - COCO Stores
Davaindia- COCO Stores 17 zotahealthcare.com
Slide 19: Operational FOFO Stores
Operational FOFO Stores 457 States Arunachal Pradesh Assam No. of Stores 1 7 OPERATIONAL FOFO STORES AS Bihar 12 ON 31.12.2021 Chhattisgarh 2 Delhi 27 Goa 1 Gujarat 55 Haryana 24 Himachal Pradesh 1 Jammu And Kashmir 2 Jharkhand 7 Karnataka 10 Kerala 15 Madhya Pradesh 67 Maharashtra 46 Meghalaya 1 Od
Slide 20: Operational COCO Stores
Operational COCO Stores 6 Cities Surat Palanpur No. of Stores 4 1 OPERATIONAL COCO STORES Mehsana 1 AS ON 31.12.2021 Legend Company Owned Company Operated (COCO) Stores 19 Operated by wholly-owned subsidiary zotahealthcare.com Davaindia Health Mart Limited
Slide 21: Management Commentary
Management Commentary Commenting on Q3FY22 financial performance and operational highlights, Management Team of Zota Health Care said, “The performance of Q3FY22 has witnessed some decrease on the topline front due to lower exports sales in the quarter, coupled with a QoQ decline in Domestic sales.
Slide 22: Industry Snapshot & Business Strategy
Industry Snapshot & Business Strategy zotahealthcare.com
Slide 23: Retail Generic Medicine Landscape in India
Retail Generic Medicine Landscape in India To achieve the objective of making available quality generic medicines at affordable prices to all, ‘Jan Aushadhi Scheme’ was launched by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India across the county. The sche
Slide 24: Impact of PMBJP
Impact of PMBJP In the financial year (2019-20), PMBJP has achieved sales of ₹258 crores (at MRP), up to 30-11-2019. This has led to savings of approximately ₹1,800 crores of the common citizens of the country. Growth in number of stores Growth in turnover Product basket Price of Janaushadhi medicin
Slide 25: Underpenetrated Generic Medicine Market
Underpenetrated Generic Medicine Market 4 pillars to drive Branded and generic mix of Indian healthcare pharma market (%) Overall India Urban India Rural India 4 As of healthcare 8 6 15 1 Accessibility 2 Affordability 3 Awarness 4 Aliments 92 94 85 • Setting up of new • Higher per capita • Rising li
Slide 26: Financial Summary
Financial Summary zotahealthcare.com
Slide 27: Profit & Loss Statement
Profit & Loss Statement Particulars (INR Lakhs) FY15 FY16 FY17 FY18 FY19 FY20 FY21 Income from Operations 5,646.3 6,473.3 7,158.0 7,785.2 8,562.9 9,511.3 10678.92 Other Income 1.4 7.7 5.6 151.9 154.5 151.3 125.97 Total Income 5,647.8 6,481.0 7,163.6 7,937.0 8,717.4 9,662.6 10804.89 Operating Expense
Slide 28: Balance Sheet & Key Ratios
Balance Sheet & Key Ratios Particulars (INR Lakhs) FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 Share capital 1,196.9 1,436.3 1,436.3 1,436.3 1,754.3 1,754.3 2,456.0 2,456.0 Reserves and Surplus 384.2 395.7 707.8 1,262.0 5,223.4 5,138.2 4,426.9 4,173.6 Non-current liabilities 521.3 548.7 272.7 466.8 64.7
Slide 29: Thank You
Thank You Contact Information Mr. Himanshu Zota / Mr. Ashvin Variya "ZOTA HOUSE", 2/896, Hira Modi Street, Sagrampura, Surat-395 002(Gujarat) cszota@zotahealthcare.com www.zotahealthcare.com